The Claim
Semaglutide initiation is associated with a 12.8 mg/dL reduction in total cholesterol levels over a period of 13 to 24 months in adults with and without type 2 diabetes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Adults who start taking semaglutide, whether or not they have type 2 diabetes, experience a 12.8 mg/dL decrease in total cholesterol levels after 13 to 24 months of use.
See the scientific wording
Semaglutide initiation is associated with a 12.8 mg/dL reduction in total cholesterol levels over 13 to 24 months in adults with and without type 2 diabetes, indicating a potential association between semaglutide use and improved lipid profiles in routine clinical practice.
Semaglutide lowers the liver's production of cholesterol and increases the removal of bad cholesterol from the blood, leading to lower total cholesterol levels.
What the research says
1 studyPeople who started taking semaglutide ended up with lower cholesterol levels after about a year and a half — exactly what the claim says. The study found this happened in real patients, not just in controlled trials.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.